Noile-Immune Biotech Inc. (4893.T)
Tokyo · JPY · Healthcare · Biotechnology
¥88 (+1.15%) as of
Key statistics
- Market cap
- 3.82B
- Forward P/E
- -3.03
- EPS (TTM)
- -17.61
- Dividend yield
- 0.00%
- 52-week range
- 85.00 – 217.00
- Beta
- 0.30
- Revenue (TTM)
- 1M
- Profit margin
- 0.00%
- Analyst target
- ¥440
- Volume
- 154.40k
About Noile-Immune Biotech Inc.
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Minato, Japan
- Employees
- 23
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.